Qiagen : Very solid Q1 results. FY 2024 guidance confirmed. Return to growth path only in H2
>Solid Q1 figures above expectations and guidance - Qiagen reported a set of solid Q1 results. Sales came in at $459m, above our ($ 456m) and the consensus estimates ($ 458m). Y-o-y, sales declined as expected by 5%, reflecting challenging macro demand trends and predominantly burdened by declining instrument sales (-10% to $50m). Looking at CER sales of $ 462m, Q1 2024 came in some 1.5% as guided by the company ($ 455m).Adjusted operating income of $ 118m was sl...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.